Approximately 80% of the shareholders of Vickers present at the meeting of Vickers shareholders in connection with the business combination voted in favor of the business combination.   Scliex’s shares of common stock and warrants are expected to begin trading on the Nasdaq Capital Market on Read More

Scilex Holding Company to Ring the Nasdaq Opening Bell on Friday November 11, 2022 at 9:30 a.m. ET Scilex plans to accelerate growth as a public company and advance further its non-opioid pain management therapeutic portfolio to transform the acute and chronic pain outpatient market Scilex will Read More

SEC declared Effectiveness of Vickers’s registration statement on Form S-4 Extraordinary General Meeting of Vickers Vantage Corp. I shareholders to approve the proposed Business Combination is scheduled to be held on November 9, 2022, at 10:00 a.m., Eastern Time Post-closing company will be renamed Read More

Pre-emptive pay off of the Senior Secured Notes (the “Notes”) eliminated the prior $28.0 million increase in the principal amount of the Notes PALO ALTO and SAN DIEGO, CA. September 29, 2022 /Newswire/  — Scilex Holding Company (“Scilex”), an innovative revenue-generating company focused on Read More

SP-103 receives Fast Track Designation, which makes it eligible for some or all of the following: More frequent meetings or written communication with the FDA to discuss the SP-103 development plan and ensure collection of appropriate data needed to support drug approval Eligibility for Accelerated Read More

PALO ALTO, CA. August 17, 2022 /Newswire/  — Scilex Holding Company (“Scilex”), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, today announced the signing of a Product Distribution Agreement Read More

30 million lives now covered by one of the largest national PBMs  Continue to work with this PBM to access an additional 20 million lives  The team continues to work with the national PBM’s and health plans to improve access further during 2022 with a goal to reach 250 million to 260 million lives Read More

Ancora Medical Inc. (“Ancora”) is a privately held medical technology company with an FDA approved product in February 2020, the Nerve Block Catheter Set which is indicated for surgical pain management during the pre-operative, perioperative and post-operative periods associated with general and Read More

PALO ALTO, CA. July 5, 2022 /Newswire/  — Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for Read More

Gloperba is an FDA-approved, oral medication for treating painful gout flares in adults. Gout is a painful arthritic disorder affecting an estimated 8.7 million people in the United States 1 . As gout cases increase every year, treatment requirements increase. Read More